Every 20 seconds, someone in the world loses a limb to diabetes.
25% of diabetic patients will be affected by Diabetic Foot Ulcer in their lifetime. 6% of Diabetics have a DFU, 50% of DFU’s develop infection, and 35% do not heal properly.
Diabetes & DFU
Diabetes Mellitus (DM): Affects 9.3%, or 45 million of 485 million of North Americans, increasing in incidence to 12%+ and 65 million by 2030*.
DM patients have a 25% Lifetime DFU Risk.
DIABETIC FOOT ULCER VS. VARIOUS CANCER TYPES
U.S. Annual Medical Costs ($USD – Billions)
Diabetic Foot Complications
Cuba and America Together
Mercurio Biotec, LLC
has entered into exclusive licensing agreements with the Center for Genetic Engineering and Biotechnology (CIGB), to conduct all transactions necessary to import Heberprot-P and conduct independent clinical trials authorized by the U.S. Food and Drug Administration (FDA) and commercialize in the United States.
On June 13, 2016, the United States Department of Health and Human Services and the Ministry of Public Health of the Republic of Cuba have signed a Memorandum of Understanding to foster a collaborative culture of research, innovation, and cooperation in the fields of healthcare delivery, biomedical and clinical sciences.
Meeting Global Needs
Furthermore, the aforementioned MOU addresses the development of Cooperative Health Strategies that includes Diabetes, Clinical Trials and Medical Product Regulation.